| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Matteo Fassan | Q39364695 |
| Luca Mastracci | Q40709122 | ||
| P2093 | author name string | Federica Grillo | |
| Roberto Fiocca | |||
| Francesca Sarocchi | |||
| P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Molecular classification of gastric cancer: a new paradigm | Q30500375 | ||
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 | ||
| Pathology of gastric intestinal metaplasia: clinical implications | Q33954445 | ||
| TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma | Q34044864 | ||
| Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization | Q34216289 | ||
| HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. | Q34324291 | ||
| Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma | Q35006904 | ||
| HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. | Q35111575 | ||
| Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule | Q35525379 | ||
| Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer | Q35554809 | ||
| Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 | ||
| Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma | Q35700713 | ||
| Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer | Q35768487 | ||
| HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. | Q35893399 | ||
| Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype | Q35954338 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens | Q36546068 | ||
| Gastric cancer: global pattern of the disease and an overview of environmental risk factors | Q36601935 | ||
| The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples | Q36613291 | ||
| Her2/neu testing in gastric cancer: evaluating the risk of sampling errors | Q36615782 | ||
| Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. | Q54574338 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q54709456 | ||
| Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. | Q54784146 | ||
| Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. | Q54784542 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| Early HER2 dysregulation in gastric and oesophageal carcinogenesis | Q58003579 | ||
| Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus | Q79401515 | ||
| HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy | Q81527951 | ||
| Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections | Q82547098 | ||
| Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays | Q83789922 | ||
| DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material | Q84570531 | ||
| Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status | Q87492670 | ||
| Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer | Q36778082 | ||
| Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients | Q37135262 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations | Q37388937 | ||
| Adenocarcinoma of the GEJ: gastric or oesophageal cancer? | Q38058033 | ||
| Clinical management of advanced gastric cancer: the role of new molecular drugs. | Q38263841 | ||
| Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections | Q38387459 | ||
| A global assessment of the oesophageal adenocarcinoma epidemic | Q38430776 | ||
| From Barrett metaplasia to esophageal adenocarcinoma: the molecular background | Q38579567 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis | Q39160504 | ||
| Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks | Q41088616 | ||
| HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. | Q41392945 | ||
| Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification | Q41710662 | ||
| Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer | Q42373194 | ||
| HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing | Q42431264 | ||
| Delay to formalin fixation effect on breast biomarkers | Q43280139 | ||
| Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo | Q44708292 | ||
| Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas | Q44867167 | ||
| Clinical significance of intratumoral HER2 heterogeneity in gastric cancer | Q45406819 | ||
| Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. | Q45950515 | ||
| Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl | Q46874370 | ||
| Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer | Q47673066 | ||
| Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. | Q51370319 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q51779078 | ||
| Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A | Q51912802 | ||
| Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. | Q51953747 | ||
| HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 | ||
| Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. | Q52937161 | ||
| Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). | Q53179955 | ||
| Heterogeneous Her2/Neu expression in gastric and gastroesophageal cancer. | Q53237058 | ||
| Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. | Q53463416 | ||
| Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. | Q53645618 | ||
| Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. | Q54348234 | ||
| Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 | ||
| Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. | Q54490269 | ||
| Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working. | Q54512417 | ||
| HER2 status in unusual histological variants of gastric adenocarcinomas. | Q54551587 | ||
| Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. | Q54559293 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 5879-87 | |
| P577 | publication date | 2016-07-14 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice | |
| P478 | volume | 22 |
| Q93000833 | Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases |
| Q47552119 | Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer |
| Q50433440 | Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management. |
| Q93059944 | Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions |
| Q64103596 | Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times |
| Q89879114 | HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies |
| Q38726662 | Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival |
| Q90113723 | Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutic management |
| Q59811484 | LONG-NONCODING RNAs in gastroesophageal cancers |
| Q55654316 | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. |
| Q33779412 | Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type |
| Q54269156 | Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. |
| Q51011198 | Stimulatory role of interleukin 10 in CD8+ T cells through STATs in gastric cancer. |
| Q99712042 | The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells |
| Q33733858 | Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer |
Search more.